Partial thickness sclerectomy and intravitreal anti-VEGF therapy for intractable uveal effusion syndrome

scientific article published on 24 July 2018

Partial thickness sclerectomy and intravitreal anti-VEGF therapy for intractable uveal effusion syndrome is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S10792-018-0992-1
P698PubMed publication ID30043134

P2093author name stringJing Guo
Xiaoxin Li
Xiaoguang Cao
P2860cites workTherapeutic targets in age-related macular diseaseQ24623107
Continued decline of aqueous interleukin-8 after multiple intravitreal injections of ganciclovir for cytomegalovirus retinitisQ34116888
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disordersQ34292807
A novel technique for choroidal fluid drainage in uveal effusion syndromeQ34724236
Uveal effusion syndrome. A new hypothesis concerning pathogenesis and technique of surgical treatmentQ41588526
Uveal effusion syndromeQ43160546
The surgical management of uveal effusion syndromeQ68943577
Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiologyQ73535800
UVEAL EFFUSION. 1. CLINICAL PICTUREQ76551602
Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesisQ84283942
Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization modelQ88089018
P433issue8
P304page(s)1885-1890
P577publication date2018-07-24
P1433published inInternational OphthalmologyQ15763839
P1476titlePartial thickness sclerectomy and intravitreal anti-VEGF therapy for intractable uveal effusion syndrome
P478volume39

Search more.